![]() | |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChemCID | |
ChemSpider | |
UNII | |
CompTox Dashboard(EPA) | |
Chemical and physical data | |
Formula | C15H13FN2 |
Molar mass | 240.281 g·mol−1 |
3D model (JSmol) | |
| |
|
Raseglurant (INN) (code nameADX-10059) is anegative allosteric modulator of themGlu5 receptor andderivative ofMPEP which was under development byAddex Therapeutics for the treatment ofmigraine,gastroesophageal reflux disease, anddental anxiety.[1][2][3] It reachedphase IIclinical trials for all of the aforementioned indications before being discontinued due to the observation of possible predictive signs ofhepatotoxicity in patients with long-term use.[3][4][5]
![]() | Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it. |